S
22.70
-0.27 (-1.18%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Summit Therapeutics Inc. | Bullish | Bullish |
Stockmoo Score
0.4
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 30 Jun 2024 | 575,705 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (HC Wainwright & Co., 98.24%) | Buy |
| Median | 25.00 (10.13%) | |
| Low | 19.00 (Citigroup, -16.30%) | Buy |
| Average | 29.67 (30.71%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 21.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Sep 2024 | 45.00 (98.24%) | Buy | 26.22 |
| 16 Sep 2024 | 45.00 (98.24%) | Buy | 29.48 | |
| Citigroup | 09 Sep 2024 | 19.00 (-16.30%) | Buy | 19.14 |
| Stifel | 09 Sep 2024 | 25.00 (10.13%) | Buy | 19.14 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |